Cumberland Pharmaceuticals Inc.

254 articles about Cumberland Pharmaceuticals Inc.

• Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results

  5/7/2019

  A conference call and live Internet webcast will be held on Tuesday, May 14, at 4:30 p.m. Eastern Time to discuss the results.

• Cumberland Pharmaceuticals Announces Strategic Review

  3/29/2019

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has commenced a strategic review of its branded product portfolio, as well as its roster of international partners

• Cumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%

  2/26/2019

  Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care, announced fourth quarter and full year 2018 financial results.

• Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results

  2/19/2019

  Cumberland Pharmaceuticals Inc. announced that it will release fourth quarter and annual 2018 financial results after the market closes on Tuesday, February 26, 2019.

• Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results

  11/13/2018

  Cumberland Pharmaceuticals Inc. today announced third quarter 2018 financial results and Company update.

• 

  FDA Action Alert: Theravance's Approval, Mallinckrodt and Aquestive

  11/12/2018

  The Food and Drug Administration is taking care of a few approvals and committee meetings ahead of the Thanksgiving holiday week. They include drugs for COPD, a pain drug, and a sublingual film formulation of a well-known drug for erectile dysfunction. Here’s a look.

• Cumberland Pharmaceuticals To Announce Third Quarter 2018 Financial Results

  11/7/2018

  Cumberland Pharmaceuticals Inc.announced today that it will release third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. 

• Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals

  11/6/2018

    [06-November-2018]   DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV ® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Unde

• Cumberland Pharmaceuticals Appoints Adam Haeberle, Ph.D. as New Senior Executive

  8/13/2018

  Biopharmaceutical Veteran Appointed as Director of Clinical and Regulatory Affairs

• Cumberland Pharmaceuticals To Announce Second Quarter 2018 Financial Results

  8/7/2018

  Cumberland Pharmaceuticals Inc. announced that it will release second quarter 2018 financial results after the market closes on Tuesday, August 14, 2018.

• Cumberland Pharmaceuticals Appoints New Senior Executive

  5/7/2018

  Pharmaceutical veteran to lead Cumberland's Hospital Sales Force

• Cumberland Pharmaceuticals To Announce First Quarter 2018 Financial Results

  5/1/2018

  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2018 financial results after the market closes on Tuesday, May 8, 2018. A conference call and live Internet webcast will be held on Tuesday, May 8, 2018, at 4:30 p.m. Eastern Time to discuss the results.

• Cumberland Pharmaceuticals Expands into Oncology Support

  4/9/2018

  FDA-approved Ethyol® and Totect® address harmful effects of cancer treatments to help improve the quality of life for oncology patients

• Newly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria

  3/26/2018

  Study supports use of Omeclamox®-Pak as first-line treatment for H. pylori

• Cumberland Pharmaceuticals Reports 25% Revenue Growth For The Full Year 2017

  3/6/2018

  Cumberland Pharmaceuticals Inc. announced fourth quarter and full year 2017 financial results. Net Revenues for the year ended December 31, 2017 were $41.2 million, a 25% increase over the prior year period.

• Cumberland Pharma Release: Newly Published Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity for Multiple Myeloma Patients

  1/30/2018

  The study, led by Ehsan Malek, MD at Case Western Reserve University, assessed multiple myeloma patients receiving high dose melphalan followed by auto-HTC.

• Cumberland Pharma Reports 27% Revenue Growth in the Third Quarter

  11/8/2017

  Cumberland Pharma announced third quarter 2017 financial results with Net Revenues of $11.2M, up 27% over the prior year quarter.

• Cumberland Pharmaceuticals to Announce Third Quarter 2017 Financial Results

  11/1/2017

  A conference call and live Internet webcast will be held on Tuesday, November 7, 2017, at 4:30 p.m. Eastern Time to discuss the results.

• Cumberland Pharmaceuticals Launches Promotion Of Totect In The U.S. For Emergency Oncology Intervention

  9/25/2017

• Clinigen And Cumberland Pharmaceuticals Launch Totect In The U.S. For Emergency Oncology Intervention

  9/25/2017